PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

C-reactive protein and risk of ovarian cancer: A systematic review and meta-analysis.

Abstract Although several studies have suggested an association between elevated C-reactive protein (CRP) and ovarian cancer risk, others have yielded contradictory results. To address this issue, we conducted a meta-analysis.
PMID
Related Publications

Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies.

C-reactive protein and risk of fracture: a systematic review and dose-response meta-analysis of prospective cohort studies.

Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.

Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies.

C-reactive protein and risk of breast cancer: A systematic review and meta-analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28834887
OWN - NLM
STAT- MEDLINE
DA  - 20170823
DCOM- 20170912
LR  - 20170912
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 34
DP  - 2017 Aug
TI  - C-reactive protein and risk of ovarian cancer: A systematic review and
      meta-analysis.
PG  - e7822
LID - 10.1097/MD.0000000000007822 [doi]
AB  - BACKGROUND: Although several studies have suggested an association between
      elevated C-reactive protein (CRP) and ovarian cancer risk, others have yielded
      contradictory results. To address this issue, we conducted a meta-analysis.
      METHODS: Studies were identified by searching PubMed and EMBASE up to July 2017
      without language restrictions. Six case-control studies and 1 cohort study were
      included, including 1898 ovarian cancer cases. Pooled risk estimates were
      generated by using the fixed-effect model or the random-effect model based on the
      heterogeneity between studies. RESULTS: As our data shown, the combined ORs were 
      1.04 (95%CI: 0.90-1.21) and 1.34 (95% CI: 1.06-1.70) for the risk in the second
      and third tertiles of CRP with those in the bottom tertile, respectively.
      Subgroup analysis showed that with respect to the top tertile of CRP level, the
      association was significant for studies obtaining CRP from serum (OR=1.99; 95%
      CI: 1.30-3.07), conducted in the USA (OR = 1.41; 95% CI: 1.15-1.72), using
      high-sensitivity immunotubidimetric assay (OR = 1.37; 95% CI: 1.14-1.64), using
      Hs-CRP (OR = 1.46; 95% CI: 1.21-1.75) and with follow-up period longer than 10
      years (OR = 1.41; 95% CI: 1.18-1.70). CONCLUSION: Collectively, our findings
      propose that serum CRP levels may serve as an indicator of ovarian cancer risk.
      Further studies are needed to definitively identify the role of CRP in the
      etiology of ovarian cancer.
FAU - Li, Jing
AU  - Li J
AD  - aDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University,
      Zhengzhou, Henan Province bReproductive Center, Department of Obstetrics and
      Gynecology, Sun Yet-Sen Memorial Hospital, Guangzhou, Guangdong Province
      cDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of
      Zhengzhou University, Zhengzhou, Henan Province, China.
FAU - Jiao, Xuedan
AU  - Jiao X
FAU - Yuan, Zhongfu
AU  - Yuan Z
FAU - Qiu, Haifeng
AU  - Qiu H
FAU - Guo, Ruixia
AU  - Guo R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 9007-41-4 (C-Reactive Protein)
SB  - AIM
SB  - IM
MH  - C-Reactive Protein/*analysis
MH  - Female
MH  - Humans
MH  - Ovarian Neoplasms/*blood
MH  - Risk Factors
PMC - PMC5572009
EDAT- 2017/08/24 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/08/24 06:00
AID - 10.1097/MD.0000000000007822 [doi]
AID - 00005792-201708250-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Aug;96(34):e7822. doi: 10.1097/MD.0000000000007822.